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A B S T R A C T
Aortic stenosis (AS) is one of the commonest forms of acquired valvular heart disease. Aortic valve
replacement (AVR) is the treatment of choice for symptomatic severe AS. Conservative management is
usually advocated for asymptomatic severe AS. But there are data on predictors to identify subsets of
asymptomatic AS patients at high risk of cardiac events in whom early surgical intervention is
warranted. Non-invasive tests like exercise stress test, exercise echocardiography will help us to identify
those who are at high risk of developing early symptoms due to LV dysfunction and also those at high risk
of sudden death. In this article, an attempt is made to review the literature on this subset of
asymptomatic severe AS to help clinicians to decide regarding the need for early aortic valve
replacement in them.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Patients of severe valvular aortic stenosis (AS) with symptoms
such as syncope, angina or heart failure carry grave prognosis.1
Aortic valve replacement (AVR) is known to improve survival and
quality of life in them.2 Patients of asymptomatic AS with normal
left ventricular (LV) function are a heterogeneous group with
very few of them being at a high risk of sudden death and some
of them at risk of developing early symptoms due to progressive
myocardial dysfunction. The optimal timing of surgery in this
subset of patients is debatable. Asymptomatic subjects need to be
examined for denial or downplay of symptoms and also some
of them may restrict activities to avoid occurrence of symptoms.
The risk vs. beneﬁt of AVR needs to be assessed in asymptomatic
individuals keeping in mind the operative risk, morbidity related
to valve prosthesis and the risk related to the use of oral
anticoagulants.
The risk of AVR in cases of uncomplicated AS is 1–2% at high
volume centres3 and 3–4% at low volume surgical centres.4 The
reported incidence of thromboembolism and bleeding risk related
to anticoagulation in the setting of mechanical valve in aortic
position is 1.1 and 4.6/100 patient-years respectively.5 The
bleeding risk increases signiﬁcantly in the elderly (age 75 yrs).* Corresponding author at: Apollo Main Hospitals, Chennai, No: 21, Greams Lane,
Off Greams Road, Chennai 600006, India.
E-mail address: isathya@hotmail.com (I. Sathyamurthy).
http://dx.doi.org/10.1016/j.ihj.2016.05.006
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).The incidence of infective endocarditis has been reported to be
0.27% per patient-year in western countries.6
The risk of development of complete heart block with need for
pacemaker implantation is high in patients who have left bundle
branch block (LBBB) and calciﬁcation extending into the interven-
tricular septum. Surgical expertise is required to enlarge annular
size for those with small aortic annulus which will add to the
surgical risk. Another important factor to consider is management
of anticoagulation status. Surgical expertise and proper monitoring
of anticoagulation status may not be readily available in many
rural and semiurban towns in developing countries. These are the
issues which raise the question whether we should operate on
asymptomatic patients with severe AS as they have less than 1%
risk of sudden death.
Early AVR however is expected to result in regression of LV mass.
The chances of developing LV dysfunction with AVR are less which
may result in improved long-term survival.7 Certain variables
identiﬁed as markers of sudden death are LBBB, associated coronary
artery disease (CAD), non-sustained ventricular tachycardia by
Holter monitoring and densely calciﬁed aortic valve (AV). In severe
AS certain factors such as age above 50 years, dense calciﬁcation
of AV, associated risk factors like hypertension, dyslipidemia and
CAD8 were shown to result in rapid progression of symptoms.
2. Natural history of asymptomatic AS
Natural history of patients with asymptomatic severe AS is
shown in Table 1. Various studies differed in their design, inclusion open access article under the CC BY-NC-ND license (http://creativecommons.org/
Table 3
Exercise testing in asymptomatic severe AS.
Positive if patient develops
 Symptoms
 Complex ventricular arrhythmias
 BP failed to rise by 20 mmHg
 Fall in systolic BP
 > 1 mm horizontal/downsloping ST #
2 yrs event free survival 19% if test is
positive
85% if test is negative
(Amato et al.13)
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approximately one third of patients become symptomatic
within 2 years9 and two-thirds of them were reported to have
had either AVR or sudden cardiac death within 5 years.8,11,12
Survival in asymptomatic unoperated patients was reported to
be 99%, 98% and 93% at the end of 1, 2 and 5 years respectively.11
It is interesting to note that survival in these patients was
noted to be similar to age and sex matched healthy population.11
Long-term prognosis however worsens with the onset of
symptoms.
Risk of sudden death in asymptomatic severe AS observed in
various prospective and retrospective studies is shown in
Table 2. Sudden death rate per year ranged between 0.2% and
3.1%. Pellikka et al.11 reported sudden death of 1% per year during
5 years follow-up in 622 cases of asymptomatic AS with a peak AV
velocity of 4 m/s.
Symptoms occur in patients with AS and normal LV systolic
function when the stenosis is severe (valve area is <1.0 cm2,
the jet velocity is over 4.0 m/s, and the mean transvalvular
gradient 40 mmHg). However, some patients may become
symptomatic when the stenosis is even moderately severe,
particularly if there is coexisting aortic regurgitation. In
Rosenhek’s study,18 some patients showed increase in mean
gradients as much as 15–19 mmHg per year without progression
of symptoms. Similarly, some patients had little or no progres-
sion in symptoms though the average rate of decline in valve
area observed was 0.1 cm2/yr.18
Taniguchi et al.19 reported 5-year outcomes of CURRENT AS
(Contemporary Outcomes after Surgery and Medical Treatment in
Patients with Severe Aortic Stenosis) registry involving
1808 patients of asymptomatic severe AS who were initially
treated either conservatively (n = 1517) or with AVR (n = 291). The
authors found a higher rate of mortality (26.4% vs. 15.4%; p = 0.009)
and hospitalizations for heart failure (19.9% vs. 3.8%; p < 0.001) at
5 years of follow-up in patients who were managed conservatively
compared to those who underwent AVR. These data seemingly
conﬂict with recommendations of watchful waiting for the
development of symptoms.Table 2
Risk of sudden death in asymptomatic severe AS.
Study Design No. of pts Mean FU  SD (m
Rosenhek et al.8 P 128 22  18 
Amato et al.13 P 66 23.6  12.5 
Lancellotti et al.14 P 69 15  7 
Pellikka et al.11 R 622 64.8  48 
Pai et al.15 R 338 42 
Lancellotti et al.16 P 163 20  19 
Ciofﬁ et al.17 P 209 22  13 
Rosenhek et al.18 P 116 41 (26–63) 
P, prospective; R, retrospective.
Table 1
Natural history of asymptomatic severe AS.
Symptom deﬁnition Cardiac event (or) end point deﬁnition
Pellika et al.9 Ang, Dys, syncope AVR, cardiac death sec to AS 
Otto et al.10 Ang, HF, sync, near syn AVR, cardiac death 
Rosenhek et al.8 NA AVR, cardiac death and
non-cardiac death
Pellika et al.11 Ang, Dys, syncope Symptom development,
AVR, cardiac death
HF-Heart failure3. Role of non-invasive testing
3.1. Electrocardiography (ECG)
In a multivariate analysis, left ventricular hypertrophy (LVH) as
per Romhilt and Estes criteria was found to be an independent
predictor of early development of symptoms.20 However, the
sensitivity of detecting LVH by ECG was found to be as low as 40%.
Recently, by 24 h continuous ECG monitoring, it was shown that
Tp-e interval, Tp-e/QT and Tp-e/QTc ratio can be novel indicators
for prediction of ventricular arrhythmias and mortality. It was
shown that Tp-e/QTc ratio had signiﬁcant positive correlation with
mean aortic gradient.21
3.2. Exercise testing
The development of symptoms and abnormal BP response to
exercise were associated with poor outcomes. The appearance of
symptoms, complex ventricular arrhythmias, fall in systolic BP or
failure of BP to rise by 20 mmHg during exercise and 1 mm ST
depression during exercise were found to have 2 year event free
survival of only 19% as reported by Amato et al.13 (Table 3). The 2-
year survival was 85% when the exercise test was negative.
Symptoms appearing during stress test predicted development of
symptoms in 57% of asymptomatic patients during 1-year follow-
up. However, the value of stress ECG was noted to be limited inonths) Events
AVR
Death without
preceding symptoms
Sudden death
rate per year
59 1 0.43%
N/A 4 3.1%
12 2 2.3%
352 11 0.33%
99 N/A 13.3%
57 3 1.1%
72 2 0.52%
90 1 0.2%
 Symptom-free survival
(%)
Event-free survival (%)
1 yr 2 yrs 5 yrs 1 yr 2 yrs 3 yrs 4 yrs 5 yrs
86  3 62  6 93  2
93  5 67  10 34  15
67  5 56  5 33  5
82 67 33 80 63 25
Table 4
Exercise testing to predict symptoms within 12 months in patients with asymptomatic AS.22
Sensitivity (%) Speciﬁcity (%) Positive predictive
accuracy (%)
Negative predictive
accuracy (%)
Limiting symptoms 72 78 57 87
Age 70 yrs in speciﬁc activity scale
Class I and limiting symptoms
65 93 79 86
Systolic BP decline of <20 mmHg from baseline 39 82 48 78
ST segment depression 2 mm 40 79 45 77
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testing in predicting onset of symptoms.22
3.3. Echocardiography (echo)
Valve morphology by echo can be a predictor of cardiac events.
The degree of AV calciﬁcation may actually help to plan optimal
timing of surgery. Echo criteria of aortic jet velocity, aortic valve
area (AVA) and rate of change of velocity over time have been
found to predict clinical outcomes.10 Rate of progression of jet
velocity of 0.3 m/s/yr and decrease in AVA of 0.2 cm2/yr help us to
identify those patients who are likely to develop early symptoms.
There was no association found between LV diastolic dysfunction
and deterioration of symptoms in asymptomatic AS patients. Left
atrial (LA) size and LA area >12.2 cm2/m2 have been reported to
predict early occurrence of cardiac events.23,24 Tissue Doppler-
derived strain imaging is useful to assess regional and global LA
function in normal subjects and in increased afterload states such
as hypertension and hypertrophic cardiomyopathy.25 In the study
by Todaro et al.,26 they found that there was a reduction in LA
reservoir function and increased LA stiffness independent of LA
size in patients of asymptomatic AS. Though the global longitu-
dinal strain of LV is a strong predictor of prognosis, they suggested
that LA functions can be included as part of echocardiographic risk
stratiﬁcation in AS.
The onset of LV systolic dysfunction over a period of time due to
inappropriate high LV muscle mass (>110%) can also predict early
onset of symptoms. Excessively high LV mass is an independent
predictor of adverse prognosis. MicroRNAs (miRs) play crucial role in
the regulation of LVH. However, few circulating miRs have been
established as predictors of LVH in AS. Circulating levels of miR-1,
miR-133 and miR-378 were decreased in AS patients and miR-378
predicts LVH independent of transaortic gradients. Further prospec-
tive studies are needed to elucidate whether these circulating
miRs affect clinical outcomes.27 Another important echo variable is
impaired longitudinal myocardial strain (15.9%), which has been
shown to predict poorer outcomes.23 Further studies are necessary
to assess prognostic value and utility of this variable.
Hachicha et al.24 introduced a new parameter the ‘‘valvulo-
arterial impedance’’ (ZVa) which takes into account the severity of
valve stenosis and systemic vascular resistance. A valvulo arterial
impedance 4.9 mmHg/ml/m2 was noted to have worst prognosis
and is mainly applicable in patients of low ﬂow, low gradient AS
with preserved LV function. However, only a minority of this
subset of patients are asymptomatic. The role of hypertension in
patients with AS is debatable. It is important to consider double LV
load in such patients, valvular load imposed by the valve stenosis
and an arterial load imposed by coexisting systemic hypertension.
In the study by Zito et al.28 on ‘‘Prognostic Signiﬁcance of
Valvuloarterial Impedance and Left Ventricular Longitudinal
Function in Asymptomatic Severe Aortic Stenosis Involving
Three-Cuspid Valves’’, they showed that an increased Zva and
reduced LV longitudinal strain increased the risk of events.
However, the authors cautioned about the results of the study,
as the number of patients followed up were small and the fact thatpresence of CAD was not taken into account while interpreting the
data.
3.4. Exercise echocardiography
An increase in mean aortic gradient of >18 mmHg and decrease
in aortic valve area of <0.75 cm2 at peak exercise were shown to
predict occurrence of early cardiac events as reported by
Lancellotti et al.14 Fig. 1 (ﬂow chart) shows non-invasive stress
testing in patients of asymptomatic AS.29
3.5. Electronic beam computed tomography
In patients of asymptomatic AS calcium score of 1100
Agatston units has 82% speciﬁcity and 93% sensitivity as an
independent predictor for survival,30 death, need for AVR and early
onset of symptoms during next 2 years.
3.6. Cardiac magnetic resonance imaging (CMR)
Determination of myocardial perfusion reserve by CMR was
assessed in a prospective study31 of 46 patients with severe AS.
Though CMR can identify and quantify distribution of myocardial
ﬁbrosis with gadolinium enhancement sequences, there were no
studies reported in asymptomatic AS patients using this technique
to guide clinical decision making. Further studies are needed to use
CMR for assessment of risk stratiﬁcation in routine clinical
practice.
3.7. Brain natriuretic peptide (BNP)
Elevated BNP levels were found to have signiﬁcant prognostic
value in patients with asymptomatic severe AS. The study by
Monin et al.32 attempted to develop a risk score based on female
gender, annual rate of progression of aortic jet velocity by echo and
BNP levels. Asymptomatic severe AS patients had 9 months
symptom-free survival of 90% with BNP or NT Pro BNP levels
<130 pg/ml and <80 pmol/l respectively as reported by Bergler-
Klein et al.33 Serial measurements of BNP might add additional
information to identify optimal timing of AVR.34
3.8. Exercise BNP
Capoulade et al.35 concluded from their study that peak exercise
BNP levels provide signiﬁcant incremental prognostic value
beyond what was observed by demographic, echocardiographic
and resting BNP levels.
What do the guidelines recommend (Table 5)
According to 2014 ACC/AHA valve guidelines,36 asymptomatic
severe AS patients fall into Stage C aortic stenosis. This is further
subdivided into C1 – patients with normal LV function and C2 –
patients with reduced LV function.
1) AVR is recommended for asymptomatic severe AS and LVEF
<50% (Stage C2 disease category) – Class I – Level B indication.
Fig. 1. Flow chart shows non-invasive stress testing in asymptomatic severe AS with preserved LV function.29
Table 5
Asymptomatic severe AS patients at high risk.36
Risk factor High risk value Guideline recommendation for AVR
Valve assessment
Peak jet velocity >5 m/s AHA IIb
AV area <0.6 cm2 AHA IIb
Rate of progression of jet velocity >0.3 m/s/year ESC IIa (moderate–severe AS)
Degree of valve calciﬁcation Dense – all cusps
Valvulo arterial impedance >4.5–4.9 mmHg/mm/m2
LV assessment
LV systolic dysfunction EF < 50% ESC I and AHA I
LVH >15 mm without high BP ESC IIb
LV mass >110% expected for body size and gender
Strain Global longitudinal strain <15.9%
Indexed LA area >12.2 cm2/m2
Stress test
TMT Symptoms ESC I and AHA IIb
Fall in BP ESC IIa and AHA IIb
Complex arrhythmias ESC IIb
Exercise echo Mean pressure increase by 18–20 mmHg
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disease category) when undergoing other cardiac surgery –
Class I – Level B indication.
3) AVR is reasonable in asymptomatic patients with severe AS
(Stage C1 disease category) in the following subset of patients:
(Class IIa – Level B indication)
a) Aortic velocity 5 m/s and low surgical riskb) Patient with reduced effort tolerance and a fall in BP on
exercise
c) In patients with rapid disease progression
Patients with normal LV systolic function without symptoms
need transthoracic echocardiography at intervals of 6 months to
1 year.
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Should patients of asymptomatic severe AS with normal LVEF
be subjected to AVR is debatable. Certain prognostic markers have
been identiﬁed with newer non-invasive modalities which will
help us to identify patients at high risk of sudden death and those
who are likely to develop early symptoms due to worsening of LV
function. Data is lacking in identifying one or two variables as risk
factors for sudden death or to identify those at high risk of
developing early symptoms warranting early AVR.37 Further
studies are needed to identify adverse outcomes in asymptomatic
cases of AS with normal LVEF who are subjected to early AVR.
Asymptomatic patients require frequent monitoring and close
watch for progression of disease. ‘‘Wait and watch policy’’ is best in
these cases.
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